Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)
Status:
Terminated
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Patients with chronic HBV infection will receive either ARC-520 alone or ARC-520 in
combination with other treatments such as entecavir (ENT) or tenofovir (TDF) and/or pegylated
interferon (PEG IFN) alpha 2a therapy, and be evaluated for safety and efficacy.